Opinion|Videos|July 22, 2024
Overview of DESTINY-Breast06
Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
- Based on the above data, how might this impact practice patterns in HER2-low and HER2 ultra-low disease?
- Would the avail of first-line T-DXd for HER2-low and HER2 ultra-low patients influence your approach in the number of regimens of endocrine therapy you recommend to patients?
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
3
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
4
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
5